 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...110111112113114115116117118119120...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date, Metastases: Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 5, 2018
P2, N=21, Terminated, Sponsor: Julie E. Bauman, MD, MPH
Initiation date: Oct 2013 --> Sep 2011 | Trial primary completion date: Oct 2016 --> Jan 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, cetuximab biosimilar / CinnaGen
New P3 trial, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Jan 5, 2018
P3, N=234, Not yet recruiting, Sponsor: Cinnagen
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jan 5, 2018
P2, N=100, Active, not recruiting, Sponsor: RenJi Hospital
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Monotherapy: Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 3, 2018
P2, N=29, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=17, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 2013 --> Sep 2011 | Trial primary completion date: Oct 2016 --> Jan 2016 N=120 --> 17
- utomilumab (PF-05082566) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, IO biomarker, Metastases: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 29, 2017
P1, N=32, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=120 --> 17 Not yet recruiting --> Recruiting
- |||||||||| linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS
New P3 trial, Combination therapy, Metastases: An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - Dec 29, 2017
P3, N=580, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||||| New P1/2 trial: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=65, Recruiting, Sponsor: NantKwest, Inc.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 29, 2017
P3, N=460, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) (clinicaltrials.gov) - Dec 29, 2017
P3, N=750, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial termination, Trial primary completion date, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Dec 29, 2017
P2, N=2, Terminated, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Not yet recruiting --> Recruiting Initiation date: Jan 2015 --> Sep 2015 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Jan 2016
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, pemetrexed / Generic mfg.
Clinical, P2 data, Journal: Phase II randomized trial of radiation therapy, cetuximab and pemetrexed with or without bevacizumab in patients with locoregionally-advanced head and neck cancer. (Pubmed Central) - Dec 27, 2017
Adding bevacizumab increased toxicity without apparent improvement in efficacy, countering the hypothesis that dual EGFR-VEGF targeting would overcome radiation resistance, and enhance clinical benefit. Further development of cetuximab, pemetrexed, and RT will require additional prospective study in defined, high-risk populations where treatment intensification is justified.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT). (Pubmed Central) - Dec 23, 2017
Cell killing after NIR-PIT was primarily on the surface, however, APCs administered immediately after NIR-PIT penetrated deeper into tissue resulting in improved cell killing after a 2nd NIR-PIT session. This phenomenon is explained by increased vascular permeability immediately after NIR-PIT.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Surgery, Metastases: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer (clinicaltrials.gov) - Dec 21, 2017
P3, N=940, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
This phenomenon is explained by increased vascular permeability immediately after NIR-PIT. N=720 --> 940
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P3 trial, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 20, 2017
P3, N=645, Recruiting, Sponsor: Array BioPharma
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1/2 data, Trial termination, Combination therapy, Surgery, Metastases: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer (clinicaltrials.gov) - Dec 20, 2017
P1/2, N=23, Terminated, Sponsor: George Albert Fisher
N=720 --> 940 Completed --> Terminated; The response rate observed in the phase 1 portion of the study did not merit further evaluation in phase 2 portion of the study.
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial initiation date, Trial termination, Metastases: Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study (clinicaltrials.gov) - Dec 19, 2017
P2, N=7, Terminated, Sponsor: Dana-Farber Cancer Institute
Completed --> Terminated; The response rate observed in the phase 1 portion of the study did not merit further evaluation in phase 2 portion of the study. Initiation date: Sep 2010 --> Jul 2011 | Withdrawn --> Terminated; Due to slow accrual
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: CHANGE2: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer (clinicaltrials.gov) - Dec 19, 2017
P3, N=243, Active, not recruiting, Sponsor: Merck KGaA
Initiation date: Sep 2010 --> Jul 2011 | Withdrawn --> Terminated; Due to slow accrual Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, seribantumab (MM-121) / Elevation Oncology
Journal: A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. (Pubmed Central) - Dec 16, 2017
Unlike the seribantumab/cetuximab doublet, seribantumab/cetuximab/irinotecan was difficult to tolerate in this heavily pretreated population. There was limited efficacy of the combination therapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Dec 15, 2017
P=N/A, N=140, Active, not recruiting, Sponsor: Southwest Oncology Group
There was limited efficacy of the combination therapy. Trial primary completion date: Oct 2017 --> Apr 2018
- |||| golvatinib (E7050) / Eisai
Trial completion, Combination therapy: E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 15, 2017
P1/2, N=95, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Oct 2017 --> Apr 2018 Active, not recruiting --> Completed
- | Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy (clinicaltrials.gov) - Dec 14, 2017
P2, N=135, Active, not recruiting, Sponsor: Pam Cogliano
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jul 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (clinicaltrials.gov) - Dec 13, 2017
P1, N=16, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jul 2018 Trial primary completion date: Nov 2017 --> Dec 2016
- |||||| epacadostat (INCB024360) / Incyte
Enrollment open, Monotherapy, Metastases: Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) (clinicaltrials.gov) - Dec 13, 2017
P3, N=625, Recruiting, Sponsor: Incyte Corporation
Trial primary completion date: Nov 2017 --> Dec 2016 Not yet recruiting --> Recruiting
- |||||| Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Trial initiation date, Metastases: Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (clinicaltrials.gov) - Dec 12, 2017
P3, N=688, Recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Sep 2017
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
New P1/2 trial, Metastases: MCC-19178: Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 12, 2017
P1/2, N=52, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Dec 11, 2017
P1b, N=14, Active, not recruiting, Sponsor: James J Lee
Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Sep 2017 Trial primary completion date: Jun 2018 --> Jun 2016
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
New P2 trial, Combination therapy, Metastases: Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (clinicaltrials.gov) - Dec 8, 2017
P2, N=40, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||||| Opdivo (nivolumab) / BMS
Enrollment open, Combination therapy, Metastases: CheckMate 9TM: Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Dec 7, 2017
P3, N=1046, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2018 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P3 trial: PETACC-8 miR-31-3p and miR-31-5p Ancillary Study (clinicaltrials.gov) - Dec 5, 2017
P3, N=1808, Completed, Sponsor: IntegraGen SA
- | PankoMab-GEX (gatipotuzumab) / Glycotope, CetuGEX (tomuzotuximab) / Glycotope
New P1 trial, Metastases: GATTO: Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors (clinicaltrials.gov) - Dec 4, 2017
P1, N=20, Recruiting, Sponsor: Glycotope GmbH
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Neucardin (recombinant human neuregulin-1β) / Zensun
Journal: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. (Pubmed Central) - Nov 30, 2017
Previous studies identified two mechanisms of resistance to the EGFR monoclonal antibody cetuximab...Overexpression of LYN and NRG1 in cells depleted of AXL resulted in accumulation of nEGFR, rescuing the deficit induced by lack of AXL. Collectively, these data uncover a previously unrecognized role for AXL in regulating the nuclear translocation of EGFR and suggest that AXL-mediated SFK and NRG1 expression promote this process.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. (Pubmed Central) - Nov 30, 2017
P3
These phase 3 trial results point to little benefit to current EGFR-targeted agents in an unselected patient population, and highlight the need for predictive biomarkers in the treatment of esophageal cancer. clinicaltrials.gov Identifier: NCT00566852.
- |||||||||| epacadostat (INCB024360) / Incyte
New P3 trial, Monotherapy, Metastases: Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) (clinicaltrials.gov) - Nov 30, 2017
P3, N=625, Not yet recruiting, Sponsor: Incyte Corporation
- | CPGJ-602 / 3SBio
New P1 trial, Metastases: A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 29, 2017
P1, N=21, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Verzenio (abemaciclib) / Eli Lilly
New P2 trial, Monotherapy, Metastases: ABORL: Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (clinicaltrials.gov) - Nov 29, 2017
P2, N=25, Not yet recruiting, Sponsor: Centre Leon Berard
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (clinicaltrials.gov) - Nov 28, 2017
P1/2, N=90, Active, not recruiting, Sponsor: Western Regional Medical Center
clinicaltrials.gov Identifier: NCT00566852. Trial primary completion date: Oct 2017 --> Jun 2018
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date, Metastases: Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 27, 2017
P2, N=30, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Trial primary completion date: Oct 2017 --> Jun 2018 Trial primary completion date: Aug 2016 --> Aug 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
Phase classification, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: DUCRO-HN: Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (clinicaltrials.gov) - Nov 22, 2017
P1/2, N=69, Not yet recruiting, Sponsor: Azienda Ospedaliero-Universitaria Careggi
Trial primary completion date: Aug 2016 --> Aug 2018 Phase classification: P2 --> P1/2 | Initiation date: Jun 2017 --> Jan 2018 | Trial primary completion date: Jun 2021 --> Jan 2022
- | CDX-3379 / Celldex
Enrollment open, Combination therapy, Metastases: A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 21, 2017
P2, N=30, Recruiting, Sponsor: Celldex Therapeutics
Phase classification: P2 --> P1/2 | Initiation date: Jun 2017 --> Jan 2018 | Trial primary completion date: Jun 2021 --> Jan 2022 Not yet recruiting --> Recruiting
- |||||||||| Opdivo (nivolumab) / BMS
New P3 trial, Combination therapy, Metastases: CheckMate 9TM: Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Nov 21, 2017
P3, N=1046, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Stivarga (regorafenib) / Bayer
Trial primary completion date, Combination therapy, Metastases: Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) - Nov 18, 2017
P1b, N=44, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2017 --> Jan 2017
- ||| napabucasin (BBI608) / Sumitomo Pharma
Enrollment closed, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Nov 14, 2017
P2, N=150, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Aug 2017 --> Jan 2017 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN (clinicaltrials.gov) - Nov 14, 2017
P2, N=38, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| epacadostat (INCB024360) / Incyte
New P3 trial, Combination therapy, Metastases: Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) (clinicaltrials.gov) - Nov 14, 2017
P3, N=550, Not yet recruiting, Sponsor: Incyte Corporation
- Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial withdrawal: Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 13, 2017
P1/2, N=0, Withdrawn, Sponsor: Julie E. Bauman, MD, MPH
Recruiting --> Active, not recruiting N=62 --> 0 | Not yet recruiting --> Withdrawn
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Surgery: Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation (clinicaltrials.gov) - Nov 8, 2017
P2, N=120, Recruiting, Sponsor: Wuhan Union Hospital, China
N=62 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Enrollment open, Metastases: Tumorspheres Colrec: Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 7, 2017
P2, N=90, Recruiting, Sponsor: Vejle Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab (clinicaltrials.gov) - Nov 6, 2017
P2, N=68, Completed, Sponsor: University of Zurich
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Nov 6, 2017
P1/2, N=80, Completed, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Oct 2013